Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)


Angiomax in Patients With HIT/HITTS Type II Undergoing Off-PUMP CABG




The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS) undergoing off-pump coronary artery bypass (OPCAB) surgery.

Study Status: Active, not recruiting


Condition Intervention Phase
Cardiac Disease
Coronary Artery Bypass Surgery
Drug: Angiomax (bivalirudin) anticoagulant Phase 3

Verified by The Medicines Company November, 2011

Sponsored by: The Medicines Company
Information provided by: The Medicines Company identifier: NCT00073580

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

The Cleveland Clinic
Cleveland, Ohio 44195
United States

Toval Rothschild, Ph.D.., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site